Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.43 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | IL2 | P60568 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CTSD | P07339 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5180886 | 0.92 | KDM4E (0.50) | HPGDKDM4EHRH3HTTLMNA | |
| SCHEMBL8491691 | 0.85 | HPGD (0.55) | HPGDKDM4EHRH3HTTLMNA | |
| SCHEMBL1621903 | 0.84 | KDM4E (0.50) | HPGDKDM4EHRH3HTTLMNA | |
| SCHEMBL5929328 | 0.79 | KDM4E (0.44) | HPGDKDM4EHRH3HTTLMNA | |
| SCHEMBL471881 | 0.78 | KDM4E (0.62) | HPGDKDM4EHRH3HTTLMNA | |
| SCHEMBL8444082 | 0.76 | KDM4E (0.50) | HPGDKDM4EHRH3HTTLMNA | |
| SCHEMBL5165604 | 0.75 | KDM4E (0.36) | HPGDKDM4EHRH3HTTLMNA | |
| SCHEMBL20410843 | 0.75 | KDM4E (0.59) | HPGDKDM4EHRH3HTTLMNA | |
| SCHEMBL11111052 | 0.74 | KDM4E (0.51) | HPGDKDM4EHRH3HTTLMNA | |
| SCHEMBL4748328 | 0.74 | KDM4E (0.54) | HPGDKDM4EHRH3HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771182-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | Anacor Pharmaceuticals, Inc. (US) | 2007-04-11 | — | — | EP | disclosed |
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | ANACOR PHARMACEUTICALS, INC. | 2006-01-19 | — | — | US | disclosed |
| WO-2005123095-A1 | ANTI-PARASITIC USES OF BORINIC ACID COMPLEXES | ANACOR PHARMACEUTICALS, INC. (US) | 2005-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060014723-A1 | Anti-parasitic uses of borinic acid complexes | BPGM, HRH1, HRH3 | HPGD 304/4885KDM4E 4785/4885HRH3 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.